245 related articles for article (PubMed ID: 32191635)
1. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL.
Hurtz C; Wertheim GB; Loftus JP; Blumenthal D; Lehman A; Li Y; Bagashev A; Manning B; Cummins KD; Burkhardt JK; Perl AE; Carroll M; Tasian SK
J Clin Invest; 2020 Jul; 130(7):3637-3653. PubMed ID: 32191635
[TBL] [Abstract][Full Text] [Related]
2. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
Tasian SK; Doral MY; Borowitz MJ; Wood BL; Chen IM; Harvey RC; Gastier-Foster JM; Willman CL; Hunger SP; Mullighan CG; Loh ML
Blood; 2012 Jul; 120(4):833-42. PubMed ID: 22685175
[TBL] [Abstract][Full Text] [Related]
3. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
[TBL] [Abstract][Full Text] [Related]
4. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
[TBL] [Abstract][Full Text] [Related]
5. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
[TBL] [Abstract][Full Text] [Related]
7. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
[TBL] [Abstract][Full Text] [Related]
8. mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph
Vo TT; Lee JS; Nguyen D; Lui B; Pandori W; Khaw A; Mallya S; Lu M; Müschen M; Konopleva M; Fruman DA
Mol Cancer Ther; 2017 Sep; 16(9):1942-1953. PubMed ID: 28566433
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in
Zhang Q; Shi C; Han L; Jain N; Roberts KG; Ma H; Cai T; Cavazos A; Tabe Y; Jacamo RO; Mu H; Zhao Y; Wang J; Wu SC; Cao F; Zeng Z; Zhou J; Mi Y; Jabbour EJ; Levine R; Tasian SK; Mullighan CG; Weinstock DM; Fruman DA; Konopleva M
Oncotarget; 2018 Jan; 9(8):8027-8041. PubMed ID: 29487712
[TBL] [Abstract][Full Text] [Related]
10. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
[TBL] [Abstract][Full Text] [Related]
11. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C; Sattler M; Kutok JL; DeAngelo DJ; Wadleigh M; Piciocchi A; Dal Cin P; Bradner JE; Griffin JD; Anderson KC; Stone RM; Ritz J; Foà R; Aster JC; Frank DA; Weinstock DM
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):252-7. PubMed ID: 20018760
[TBL] [Abstract][Full Text] [Related]
12. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
13. Philadelphia chromosome-like acute lymphoblastic leukemia.
Tasian SK; Loh ML; Hunger SP
Blood; 2017 Nov; 130(19):2064-2072. PubMed ID: 28972016
[TBL] [Abstract][Full Text] [Related]
14. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.
Cheng Y; Chikwava K; Wu C; Zhang H; Bhagat A; Pei D; Choi JK; Tong W
J Clin Invest; 2016 Apr; 126(4):1267-81. PubMed ID: 26974155
[TBL] [Abstract][Full Text] [Related]
15. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.
Köhrer S; Havranek O; Seyfried F; Hurtz C; Coffey GP; Kim E; Ten Hacken E; Jäger U; Vanura K; O'Brien S; Thomas DA; Kantarjian H; Ghosh D; Wang Z; Zhang M; Ma W; Jumaa H; Debatin KM; Müschen M; Meyer LH; Davis RE; Burger JA
Leukemia; 2016 Jun; 30(6):1246-54. PubMed ID: 26847027
[TBL] [Abstract][Full Text] [Related]
16. Clinical screening for Ph-like ALL and the developing role of TKIs.
Tran TH; Tasian SK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):594-602. PubMed ID: 36485164
[TBL] [Abstract][Full Text] [Related]
17. Can Ph-like ALL be effectively targeted?
Maese L; Raetz EA
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101096. PubMed ID: 31779971
[TBL] [Abstract][Full Text] [Related]
18. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
Fei F; Lim M; Schmidhuber S; Moll J; Groffen J; Heisterkamp N
Mol Cancer; 2012 Jun; 11():42. PubMed ID: 22721004
[TBL] [Abstract][Full Text] [Related]
19. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB
Leukemia; 2021 Nov; 35(11):3101-3112. PubMed ID: 33895784
[TBL] [Abstract][Full Text] [Related]
20. A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis.
Francis OL; Milford TA; Martinez SR; Baez I; Coats JS; Mayagoitia K; Concepcion KR; Ginelli E; Beldiman C; Benitez A; Weldon AJ; Arogyaswamy K; Shiraz P; Fisher R; Morris CL; Zhang XB; Filippov V; Van Handel B; Ge Z; Song C; Dovat S; Su RJ; Payne KJ
Haematologica; 2016 Apr; 101(4):417-26. PubMed ID: 26611474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
